Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03761914 |
|
Recruitment Status :
Recruiting
First Posted : December 3, 2018
Last Update Posted : March 17, 2021
|
Sponsor:
Sellas Life Sciences Group
Collaborators:
Merck Sharp & Dohme Corp.
Cancer Insight, LLC
Information provided by (Responsible Party):
Sellas Life Sciences Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2024 |
| Estimated Study Completion Date : | April 30, 2024 |